Pengcheng Shi

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

Li Xuan, Yu Wang, Fen Huang et al. · The Lancet Oncology · 2020 · 313 citations

Medicine, Hematology, Oncology +16

Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition

Jie Zha, Feili Chen, Huijuan Dong et al. · Journal of Translational Medicine · 2014 · 106 citations · Full text

Medicine, Oncology, Pharmacology +15

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial

Hua Jin, Yu Zhang, Sijian Yu et al. · Journal of Hematology & Oncology · 2023 · 71 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial

Li Xuan, Yu Wang, Kaibo Yang et al. · The Lancet Haematology · 2023 · 68 citations

Medicine, Hematology, Oncology +17

Disulfiram/copper complex activated JNK/c-jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells

Bing Xu, Pengcheng Shi, Ivo S. Fombon et al. · Blood Cells Molecules and Diseases · 2011 · 53 citations

Medicine, Oncology, Pharmacology +9